SPOTLIGHT -
Unmet Needs and Future Directions for Patients with Metastatic CSPC
Dr Gordon Brown closes his discussion on mCSPC by highlighting unmet needs in the field and ongoing initiatives that may address these needs.
A Comparison of AR Inhibitor Safety and Efficacy and Factors That Impact mCSPC Treatment Selection
A comparison of the safety and efficacy of available AR inhibitors and a discussion of factors that impact treatment selection in mCSPC.
Safety of Combination ADT/Apalutamide and Management of Adverse Events
Gordon A. Brown, DO, comments on adverse events observed after combination ADT/apalutamide treatment and how they might be managed.
Efficacy Data on Combination ADT/Apalutamide from the TITAN Trial and Real-World Analyses
A comprehensive review of efficacy data on combination therapy with ADT and the AR inhibitor apalutamide in patients with mCSPC.
Available Single-Agent and Combination Therapies for mCSPC
Dr Gordon Brown provides an overview of single-agent androgen deprivation therapy (ADT) and other regimens that may be used in combination with ADT, including androgen receptor (AR) inhibitors, for treatment of mCSPC.
An Expert Commentary on the Patient Profile and Considerations for Treatment and Management of Prostate Cancer
An expert comments on the patient profile and offers insights into how he approaches treatment and management of prostate cancer.
Introduction: A 60-Year-Old-Man with Prostate Cancer
Gordon A. Brown, DO, presents the profile of a 60-year-old man with prostate cancer.
